Plasma samples collected before treatment initiation of stage IV or unresectable stage III melanoma patients at Nantes University Hospital between January 2014 and March 2017 were included in this study. Plasma samples were collected in EDTA tubes (Greiner Bio-One, Les Ulis, France), centrifuged at 2000× g for 10 min, and frozen at −80 °C within 4 h after venepuncture.
During this time frame, detection of BRAF and NRAS mutation in the patient’s tumour was performed using a combination of allele-specific amplification and Sanger sequencing [26 (link),27 (link),28 (link)]. Our laboratory is accredited in accordance with the International Standard ISO15189.
Patients were treated either by immunotherapy (nivolumab monotherapy or nivolumab–ipilimumab combination) or by targeted therapy for BRAF-mutated patients (vemurafenib alone or vemurafenib + cobimetinib or dabrafenib + trametinib).
During this time frame, detection of BRAF and NRAS mutation in the patient’s tumour was performed using a combination of allele-specific amplification and Sanger sequencing [26 (link),27 (link),28 (link)]. Our laboratory is accredited in accordance with the International Standard ISO15189.
Patients were treated either by immunotherapy (nivolumab monotherapy or nivolumab–ipilimumab combination) or by targeted therapy for BRAF-mutated patients (vemurafenib alone or vemurafenib + cobimetinib or dabrafenib + trametinib).
Free full text: Click here
